Company Overview
Snapshot
Founded in August 2008 by Shimon Eckhouse and Ronen Eckhouse, Rapid Medical operates with 51–200 employees. The company has raised $82.31M across 7 funding rounds from 14 investors.
Business overview
Rapid Medical develops neurovascular medical devices focused on safety and efficacy for patients and physicians. The company's product portfolio includes distal access catheters, adjustable remodeling mesh for microcatheters, and steerable guidewires. Its offerings, such as the Tigertriever 13, Comaneci, and Drivewire (Columbus outside the U.S.), are designed to treat vascular diseases with less invasive interventional approaches, serving the health tech and life sciences sector.
Strategic signal
Rapid Medical has expanded its global market reach and product validation. In December 2023, the company announced Japanese approval and an exclusive partnership with Kaneka for its TIGERTRIEVER device, following approval in China for the same adjustable thrombectomy device in August 2023. This strategic expansion into key Asian markets signals strong international validation and commercial growth potential for its neurovascular technologies.
Log in to access full profile ›Company Intelligence Q&A
- What regulatory milestone did Rapid Medical achieve in December 2020?
- In December 2020, Rapid Medical received FDA clearance for its steerable neurovascular guidewire, the world's first such device.
- What was a key product approval for Rapid Medical in 2023?
- In August 2023, Rapid Medical gained approval in China for its adjustable thrombectomy device, TIGERTRIEVER, further expanding its market access.
- What was the latest strategic partnership announced by Rapid Medical?
- In December 2023, Rapid Medical announced an exclusive partnership with Kaneka for its TIGERTRIEVER device, coinciding with Japanese approval for the product.